Drug Type Fab fragment, Biosimilar |
Synonyms Ranibizumab biosimilar, CMAB-818, CMAB818 |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Wet age-related macular degeneration | Phase 1 | CN | 03 Jun 2021 | |
Wet Macular Degeneration | Phase 1 | CN | 03 Jun 2021 |